Research ArticleNuclear Oncology
Carbon-11-Thymidine and FDG to Measure Therapy Response
Anthony F. Shields, David A. Mankoff, Jeanne M. Link, Michael M. Graham, Janet F. Eary, Susie M. Kozawa, Minna Zheng, Barbara Lewellen, Thomas K. Lewellen, John R. Grierson and Kenneth A. Krohn
Journal of Nuclear Medicine October 1998, 39 (10) 1757-1762;
Anthony F. Shields
David A. Mankoff
Jeanne M. Link
Michael M. Graham
Janet F. Eary
Susie M. Kozawa
Minna Zheng
Barbara Lewellen
Thomas K. Lewellen
John R. Grierson


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Carbon-11-Thymidine and FDG to Measure Therapy Response
Anthony F. Shields, David A. Mankoff, Jeanne M. Link, Michael M. Graham, Janet F. Eary, Susie M. Kozawa, Minna Zheng, Barbara Lewellen, Thomas K. Lewellen, John R. Grierson, Kenneth A. Krohn
Journal of Nuclear Medicine Oct 1998, 39 (10) 1757-1762;
Carbon-11-Thymidine and FDG to Measure Therapy Response
Anthony F. Shields, David A. Mankoff, Jeanne M. Link, Michael M. Graham, Janet F. Eary, Susie M. Kozawa, Minna Zheng, Barbara Lewellen, Thomas K. Lewellen, John R. Grierson, Kenneth A. Krohn
Journal of Nuclear Medicine Oct 1998, 39 (10) 1757-1762;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer
- 89Zr-anti-{gamma}H2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma
- The Use of Novel PET Tracers to Image Breast Cancer Biologic Processes Such as Proliferation, DNA Damage and Repair, and Angiogenesis
- Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics
- 4'-[Methyl-11C]-Thiothymidine PET/CT for Proliferation Imaging in Non-Small Cell Lung Cancer
- Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung
- 18F-FLT PET/CT for Early Response Monitoring and Dose Escalation in Oropharyngeal Tumors
- Histopathologic Validation of 3'-Deoxy-3'-18F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity
- Molecular Imaging: 18F-FDG PET and a Whole Lot More
- Proliferation Imaging to Measure Early Cancer Response to Targeted Therapy
- Analysis and Reproducibility of 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer
- Imaging of Cell Proliferation: Status and Prospects
- Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol
- Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
- Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
- Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
- Kinetic Analysis of 3'-Deoxy-3'-18F-Fluorothymidine in Patients with Gliomas
- 2-[11C]Thymidine Positron Emission Tomography Reproducibility in Humans
- Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
- Kinetic Analysis of 3'-Deoxy-3'-Fluorothymidine PET Studies: Validation Studies in Patients with Lung Cancer
- Kinetic Modeling of 3'-Deoxy-3'-Fluorothymidine in Somatic Tumors: Mathematical Studies
- Imaging DNA Synthesis In Vivo with 18F-FMAU and PET
- Positron Emission Tomography in Limited-Stage Small-Cell Lung Cancer: A Prospective Study
- Prospective Feasibility Trial of Radiotherapy Target Definition for Head and Neck Cancer Using 3-Dimensional PET and CT Imaging
- In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography
- 18F-Fluorothymidine Radiation Dosimetry in Human PET Imaging Studies
- Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use
- 3'-Deoxy-3'-[18F]Fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography
- Interobserver and Intraobserver Variability in Measurement of Non-Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor Response
- 18F-FDG PET for the Diagnosis and Grading of Soft-Tissue Sarcoma: A Meta-Analysis
- 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
- In Vivo Validation of 3'deoxy-3'-[18F]fluorothymidine ([18F]FLT) as a Proliferation Imaging Tracer in Humans: Correlation of [18F]FLT Uptake by Positron Emission Tomography with Ki-67 Immunohistochemistry and Flow Cytometry in Human Lung Tumors
- Assessment of Proliferation in Vivo Using 2-[11C]Thymidine Positron Emission Tomography in Advanced Intra-abdominal Malignancies
- Validation of FLT Uptake as a Measure of Thymidine Kinase-1 Activity in A549 Carcinoma Cells
- Dynamic PET 18F-FDG Studies in Patients with Primary and Recurrent Soft-Tissue Sarcomas: Impact on Diagnosis and Correlation with Grading
- The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology
- Quantitative PET Studies in Pretreated Melanoma Patients: A Comparison of 6-[18F]Fluoro-L-Dopa with 18F-FDG and 15O-Water Using Compartment and Noncompartment Analysis
- PET in Differentiation of Recurrent Brain Tumor from Radiation Injury
- Imaging Brain Tumor Proliferative Activity with [124I]Iododeoxyuridine